Facing Challenges in Hospice Industry Around Pharmacy Services at the End of Life

Published in Hospice, News, Press Releases, on April 29, 2014

Share +

West Deptford, NJ (PRWEB) April 29, 2014

Enclara Health, a leading hospice pharmacy services provider added greater than 6,000 patients (ADC) to its national footprint in 2013 and to date, has already secured an additional 7,500 ADC for 2014, which includes three additional large national accounts.

Established in 2006, Enclara has quickly become the “go to” choice for hospices seeking a nimble and forward thinking pharmacy partner. Enclara presently services an ADC of approximately 27,000 patients, across 46 states, and offers services in both the mail order and local PBM market space.

Andy Horowitz, Founder, and CEO stated, “We attribute our continued success to our focus on exceptional customer service, as well as our ability to get in front of the reimbursement and regulatory changes currently facing the provider community, including CR 8358 and Medicare Part D.” Enclara’s daily CR 8358 reporting tool was launched on March 14, 2014. This multi-faceted tool allows for submission of a complete CMS formatted file (for those hospices that do not utilize an EMR), as well as a customized file that can be uploaded directly or indirectly into many of the leading hospice EMR programs. In addition, Enclara has developed supportive tools to help its customer base deal with the recently announced Hospice / Medicare Part D changes. Enclara is offering guidance on related / unrelated determinations, safe discontinuation guidelines for inappropriate medications, ‘drug exposure’ reviews, prior authorization assistance, and pricing options, all intended to help their clients mitigate risk. “Our ability to be forward thinking has allowed us to be lead the conversations around these initiatives.”

To further strengthen the company’s position as a leading industry provider, Horowitz recently announced that he partnered with Consonance Capital Partners, the private equity arm of Consonance Capital, a leading healthcare-focused investment firm, to replace the company’s “angel” investors and recapitalize the company. This partnership provides the financial backing to support Enclara’s growth, both internal and external through acquisitions and will help accelerate the rollout of Enclara’s service and technology enhancements in the coming months. Horowitz stated, “I am truly excited about our new partnership with Consonance. Their focus on the healthcare sector as well as their financial support will strongly position us to continue to grow, innovate and further solidify our commitment to our hospice partners.”

About Enclara Health
Enclara Health, LLC (“Enclara”) is a national full-service mail order and PBM supplier of medications and clinical services developed specifically for the hospice and palliative care industry. Enclara services some of the largest hospice providers in the country, helping to reduce pharmacy costs through a clinically driven model that enables home delivery of pharmaceuticals, as well as access to a network of over 60,000 retail and institutional pharmacies.For more information, visit http://www.enclarahealth.com.

About Consonance Capital
Consonance Capital is a healthcare investment firm that invests broadly across the healthcare landscape. Private investments, which include growth equity, leveraged buyouts, and recapitalizations, are made under the direction of Consonance Capital Partners, a private equity manager led by Mitchell Blutt, MD, Benjamin Edmands, Stephen McKenna, and Nancy-Ann DeParle. Public investments are made under the direction of Consonance Capital Management, a long/short public equity manager. Consonance Capital was established in 2005 and is located in New York City.